APR 29, 2021 1:35 PM +08

Validation of combined DNA and RNA sequencing in Myeloid neoplasms

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Unipath Specialty Laboratory
    Biography

      I joined Tata Medical centre, Kolkata in 2013 and work in the service diagnostic laboratory as a consultant pathologist, taking care of the rotuine haematopathology, lymphoma pathology,  flow cytometry and Molecular genetics.  I along with my team have been involved in developing and implementing flowcytometry based minimal residual disease assays for haematological diseases like ALL and multiple myeloma. I have stong interest in lymphoma pathology and report the lymph nodes/bone marrow aspirates/biopsies.



      Under the guidance and vision of Dr Mammen Chandy (Director TMC) I have had the opportunity of successfully setting up affordable diagnostic molecular solutions for haematological and solid tumours using the latest techniques like NGS, digital PCR. Over the last 4-5 years we have successfully established and implemented molecular driven (Ion torrent based tissue genotyping for EGFR; digital PCR based T790M assays, cfDNA based EGFR genotyping, Oncomine comprehensve myeloid assays), standard treatment of care for our patients.



      I am involved in running and teaching fellows from the fellowship courses in haematopathology and molecular pathology.


    Abstract

    Myeloid neoplasms represent a highly heterogeneous group of diseases that encompass myeloproliferative, myelodysplastic (myeloproliferative/myelodysplastic) syndrome and acute myeloid leukemias. During recent years, considerable progress has been made in understanding disease pathogenesis, genetic landscapes of disease (driver mutations) and in development of diagnostic assays and novel therapies. In this presentation, we will share our experience with Oncomine Myeloid Research assay and the analytical validation of this assay. We will also discuss why targeted NGS method brings a unique advantage for detection of multiple variant alterations and fusions using a single platform.

    Learning Objectives

    1. Understand the benefits of next-generation sequencing in the profiling of haematological malignancies

    2. Validation and user experience of combined DNA and RNA sequencing using Oncomine Myeloid Research Assay in haematological malignancies


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    Loading Comments...
    Show Resources